Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

The Enbrel biosimilar, which is branded as Erelzi ... and could free up cash in the US health system that could be spent on newer drugs as well as widening access to biologic medicines.

State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...

Enbrel’s list price rose 5.4% ... in the list price – and 10.7% net – which added $203 million to US drug spending. The biggest price increases were seen with Salix’ irritable bowel ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

This table may help to avoid unnecessary drug loss and expenditures due to ... 14 days Prescribing information Etanercept powder Enbrel (Immunex Corporation [Amgen and Wyeth Pharmaceuticals ...